热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 抗体 Biosimilar抗体

Anti-Human CD19 Monoclonal Antibody (Coltuximab)

B-lymphocyte antigen CD19,B-lymphocyte surface antigen B4,Differentiation antigen CD19,T-cell surface antigen Leu-12

价格 询价 请咨询客服
货号 S0B7124
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 宿主来源

    Human

  • 抗原名称

    CD19

  • 分子别名

    B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12

  • 细胞定位

    Cell membrane

  • Accession

    P15391

  • 抗体类型

    Recombinant mAb

  • 抗体同种型

    IgG1

  • 反应种属 ?

    Hu

  • 纯化方式

    Protein A

  • 浓度

    5 mg/ml

  • 纯度

    >95% (Determined by SDS-PAGE)

  • 内毒素含量

    <1EU/mg

  • 标记

    Unconjugated

  • 性状

    Liquid

  • 缓冲体系

    PBS pH7.4, containing no preservative

  • 储存条件

    2 to 8 °C for 2 weeks under sterile conditions;
    -20 °C for 3 months under sterile conditions;
    -80 °C for 24 months under sterile conditions.
    Please avoid repeated freeze-thaw cycles.

  • 应用

    Blocking of CD19 signaling functional assays

背景介绍

  • CD19, also known as B-lymphocyte antigen CD19 or B-Lymphocyte Surface Antigen B4, is a 95 kDa type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is encoded by the CD19 gene. It is primarily expressed on all B lineage cells, from early pro-B cells to plasma cells, and plays a crucial role in B cell development, activation, and signaling. As a co-receptor, CD19 enhances signaling through the B cell receptor (BCR) complex, lowering the threshold for B cell activation and promoting B cell proliferation and differentiation. It forms a complex with CD21, CD81, and other proteins, which helps in the recognition of antigens tagged with complement and amplifies BCR signaling. CD19 is also a biomarker for B cell-related diseases and a target for immunotherapies, including monoclonal antibodies and CAR-T cell therapies, due to its consistent expression on B cells and B cell malignancies.

评论(0)